Shares of Aptose Biosciences Inc. (NASDAQ:APTO) last traded at $1.30. The company’s performance year to date is -6.47%. The 200 day simple moving average is -13.08%. The 200 simple moving average (SMA) is considered a key indicator by traders and market analysts for determining the overall long-term trend. The price level in a market that coincides with the 200 SMA is recognized as a major support when price is above the 200 SMA or resistance when price is below the 200 SMA level.
As per recent filings, Aptose Biosciences Inc. (NASDAQ:APTO) has an insider ownership of 20.40%.
Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in patients with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada.
Aptose Biosciences Inc. (NASDAQ:APTO) has been storming Wallstreet with solid press release. Recently, the company announced that according to the March 2017 study commissioned by RetailMeNot and conducted by Forrester Consulting, the company’s mobile marketing solutions generate a three-year, risk-adjusted return on investment (ROI) of 4.3x.
The Exponential Moving Average (EMA) is similar to a simple moving average (average price over a set period) but it utilizes a weighting factor that exponentially declines from the most recent data point (recent prices are weighted higher than oil prices). EMA analysis compares the short term (5 days and 13 days), intermediate term (20 days) and long term (50 days) EMA’s. The respective EMA’s will give bullish signals when trading above trailing EMA’s and below the current price and vice versa. EMA alerts include crossovers (i.e the 5 day EMA crosses above/below the 20 day EMA) and EMA convergencies (5 day EMA equivalent to 13 day EMA). The long term and short term EMA’s of 1.07 and 1.03 are lower than the current trading price suggesting a bullish pattern in both short term as well as long term. .
The Barchart Technical Opinion rating is a 56% Buy with a Strongest short term outlook on maintaining the current direction. Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend. The market is approaching overbought territory. Be watchful of a trend reversal.
Aptose Biosciences Inc. (NASDAQ:APTO) is all set to announce its earnings on May 11/a. As per Zack’s analyst ratings, Aptose Biosciences Inc. (NASDAQ:APTO) currently has an average brokerage rating of . On a scale of 1 to 5, a rating of 1 or 2 would indicate a buy, and a rating of 4 or 5 would signify a sell recommendation. A rating of 3 would indicate a hold on the stock. The consensus target price on (NASDAQ:APTO) is $ with a high of $ and a low of $.
The relative strength index (RSI) is a momentum oscillator that is able to measure the velocity and magnitude of stock price changes. Momentum is calculated as the ratio of positive price changes to negative price changes. The RSI analysis compares the current RSI against neutral(50), oversold (30) and overbought (70) conditions. Alerts will inform you when stocks recede from oversold/overbought levels or breakthrough neutral (50). The current RSI is 75.05 suggesting a bullish price action.
As such, while we believe Aptose Biosciences Inc. (NASDAQ:APTO) represents a compelling growth story exposed to several secularly attractive markets, it would be interesting to see how it fairs for long-term investors.
Aptose Biosciences Inc. (Aptose) (NASDAQ:APTO) (TSX:APS.TO), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will release its financial results for the quarter ended March 31, 2017, on Thursday May 11, 2017 after the close of the market. The company intends to host a conference call the same day at 5:00 p.m. ET to discuss the financial results.